Revenue - Revenue from Licensing Arrangements (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended								12 Months Ended
	Mar. 31, 2020	Jun. 30, 2019	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangements and Co-Promote Agreement
Milestone payment			$ 14,946	$ 13,194	$ 12,914	$ 14,257	$ 18,730	$ 18,257	$ 15,008	$ 19,862	$ 55,311	$ 71,857	$ 73,414
YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Milestone payment			$ 15,344	$ 13,806	$ 14,621	$ 12,908	$ 13,550	$ 12,960	$ 10,589	$ 12,880
Viatris
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable		$ 18,500
Milestone payment	$ 1,500
Viatris | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Milestone payment		37,500									205,000
Viatris | Revefenacin Monotherapy (TD-4208)
Collaborative Arrangements and Co-Promote Agreement
Milestone payment											160,000
Viatris | YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Milestone payment		9,000
Viatris | YUPELRI Monotherapy | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Milestone payment											150,000
Viatris | Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Milestone payment		7,500									$ 45,000
Viatris | Future potential combination products | Development and Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Milestone payment		$ 54,000
Pfizer | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Milestone payment													$ 240,000